» Articles » PMID: 19563863

Mitochondrial Dysfunction in CA1 Hippocampal Neurons of the UBE3A Deficient Mouse Model for Angelman Syndrome

Overview
Journal Neurosci Lett
Specialty Neurology
Date 2009 Jul 1
PMID 19563863
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Angelman syndrome (AS) is a severe neurological disorder caused by a deficiency of ubiquitin protein ligase E3A (UBE3A), but the pathophysiology of the disease remains unknown. We now report that in the brains of AS mice in which the maternal UBE3A allele is mutated (m-) and the paternal allele is potentially inactivated by imprinting (p+) (UBE3A m-\p+), the mitochondria are abnormal and exhibit a partial oxidative phosphorylation (OXPHOS) defect. Electron microscopy of the hippocampal region of the UBE3A m-\p+ mice (n=6) reveals small, dense mitochondria with altered cristae, relative to wild-type littermates (n=6) and reduced synaptic vesicle density. The specific activity of OXPHOS complex III is reduced in whole brain mitochondria in UBE3A m-\p+ (n=5) mice versus wild-type littermates (n=5). Therefore, mitochondrial dysfunction may contribute to the pathophysiology of Angelman syndrome.

Citing Articles

The multifaceted role of mitochondria in autism spectrum disorder.

Khaliulin I, Hamoudi W, Amal H Mol Psychiatry. 2024; 30(2):629-650.

PMID: 39223276 PMC: 11753362. DOI: 10.1038/s41380-024-02725-z.


H-NMR-based metabolomics reveals metabolic alterations in early development of a mouse model of Angelman syndrome.

Gupta P, Barak S, Feuermann Y, Goobes G, Kaphzan H Mol Autism. 2024; 15(1):31.

PMID: 39049050 PMC: 11267930. DOI: 10.1186/s13229-024-00608-2.


UBE3A: The Role in Autism Spectrum Disorders (ASDs) and a Potential Candidate for Biomarker Studies and Designing Therapeutic Strategies.

Roy B, Amemasor E, Hussain S, Castro K Diseases. 2024; 12(1).

PMID: 38248358 PMC: 10814747. DOI: 10.3390/diseases12010007.


Stem cell models of Angelman syndrome.

Camoes Dos Santos J, Appleton C, Cazaux Mateus F, Covas R, Bekman E, da Rocha S Front Cell Dev Biol. 2023; 11:1274040.

PMID: 37928900 PMC: 10620611. DOI: 10.3389/fcell.2023.1274040.


Elevated ROS levels during the early development of Angelman syndrome alter the apoptotic capacity of the developing neural precursor cells.

Simchi L, Gupta P, Feuermann Y, Kaphzan H Mol Psychiatry. 2023; 28(6):2382-2397.

PMID: 36991133 PMC: 10611580. DOI: 10.1038/s41380-023-02038-7.


References
1.
Cornford M, Philippart M, Jacobs B, SCHEIBEL A, Vinters H . Neuropathology of Rett syndrome: case report with neuronal and mitochondrial abnormalities in the brain. J Child Neurol. 1994; 9(4):424-31. DOI: 10.1177/088307389400900419. View

2.
Keating D . Mitochondrial dysfunction, oxidative stress, regulation of exocytosis and their relevance to neurodegenerative diseases. J Neurochem. 2007; 104(2):298-305. DOI: 10.1111/j.1471-4159.2007.04997.x. View

3.
Jiang Y, Beaudet A . Human disorders of ubiquitination and proteasomal degradation. Curr Opin Pediatr. 2004; 16(4):419-26. DOI: 10.1097/01.mop.0000133634.79661.cd. View

4.
Wallace D . A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet. 2005; 39:359-407. PMC: 2821041. DOI: 10.1146/annurev.genet.39.110304.095751. View

5.
Trounce I, Kim Y, Jun A, Wallace D . Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol. 1996; 264:484-509. DOI: 10.1016/s0076-6879(96)64044-0. View